Arrowhead research collaboration

[partimefriend]

So...in the Fiscal 2015 Year End Conference Call – Prepared Remarks December 14, 2015
Chris Anzalone said Arrowhead would for 2016..... 

Enter into one corporate collaboration in MONARCH with a new compound
for combination therapy. 

I find it interesting that he speaks of the collaboration and new compound in one sentence,
is this a hint that this new compound will come from this collaboration? And who would have a compound to bring to the table for a combination thearapy? Roche did get back into the iRNA Medicines with Acquisition of Santaris, Anyone else want to give a WAG to who the deal could be  with ?

[qbeing1010]

About the Locked Nucleic Acid (LNA) Platform

Santaris Pharma’s LNA platform and drug discovery engine combines the company’s proprietary LNA chemistry with its highly specialized and targeted drug discovery capabilities to rapidly deliver drug candidates against both mRNA and microRNA, thus enabling scientists to develop drug candidates for diseases that are difficult, or impossible, to target with contemporary drug platforms such as antibodies and small molecules. The LNA platform is designed to overcome the limitations of earlier antisense and siRNA technologies, in particular through a unique combination of small size, high binding affinity and metabolic stability that allows this new class of drugs candidates to potently and specifically influence RNA targets in many different tissues without the need for complex delivery vehicles. LNA is also sometimes referred to as BNA (Bicyclic or Bridged Nucleic Acid).

About Santaris Pharma A/S

Santaris Pharma A/S uses its proprietary Locked Nucleic Acid (LNA) platform and tissue-targeting expertise to pioneer next-generation antisense product candidates. Santaris Pharma is developing a diverse pipeline of LNA therapeutics that influence the production or activity of select RNA targets to address diseases that are difficult-to-treat with conventional drug modalities. Santaris Pharma’s innovation and leadership position has attracted multiple collaborations with leading global pharmaceutical companies. Founded in 2003, Santaris Pharma is headquartered in Denmark.

[dig]

When CA talked about collaboration he mentioned 2 things 1) not many companies were far enough in the clinic to participate in a study like Monarch. 2) He made it sound as they were interested in starting with an immune system stimulator of some sort. Here is a list of drugs that are currently in development.

www.hepb.org/professionals/hbf_drug_watch.htm

I believe that it will be an immune system stimulator in phase 2

[qbeing1010]

So considering their relationship with Roche, and the new facility adjoining Roche, would you expect the compound to be RG7795 (formerly ANA773)?  Roche acquired this from Anadys in 2011.

From a Roche 2011 PR:

"Anadys is developing ANA773, an oral, small-molecule inducer of innate immunity in Phase I trials that may prove useful for treating HCV as well as other chronic infections and cancer."

[partimefriend]

Just looking around a little, thought that this was interesting.


Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B


TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), as well as improvements in surrogate laboratory markers of renal and bone safety as compared to Viread.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 12, 2016-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tenofovir alafenamide (TAF) 25 mg, an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infection.



www.gilead.com/news/press-releases/2016/1/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b

[dig]

qbeing1010



I am thinking they will partner with Roche on RG7795 first. From the Cowen and Company Healthcare Conference March 7 presentation, I got the impression we will see more than one collaboration this year. I also got the impression they are going to open new Monarch locations. It could be he was referring to the locations in Australia and New Zealand But, that was not the impression I got.

[wayne14072]

From the shareholder meeting yesterday, CA seemed very focused on and I came away with the impression that the ramp up in new personal is from the demand and interest in the DPC platform. The platform is going to be a revenue stream whereby ARWR will be able to collaborate with companies that need to get their drugs on target to specific locations in body. CA was adamant about keeping the safety profile and efficacy as the highest priority with any upcoming collaborations. This is only my opinion from what I heard and really think that everyone does not need to be focused on the day to day price of stock. ARC 520, 521, AAT, and all others are going through the correct process of how a new drug comes to market. WE all have to be patient and let the process work, our company is very aggressive and will pay off in the long run. When ARC 520 is proven there will be a bidding war from big pharma.

[holdencf]

Novartis, JNJ, GILD

[partimefriend]

Mar 6, 2016 22:58:15 GMT -5 dig said:

When CA talked about collaboration he mentioned 2 things 1) not many companies were far enough in the clinic to participate in a study like Monarch. 2) He made it sound as they were interested in starting with an immune system stimulator of some sort. Here is a list of drugs that are currently in development.

www.hepb.org/professionals/hbf_drug_watch.htm

I believe that it will be an immune system stimulator in phase 2

Innate Immune Defense Pathway: Compounds that activate the innate immune system


Spring Bank Pharmaceuticals, USA                                         SB9200                                                    Phase II
springbankpharm.com

Nice Pick Dig.